Growing awareness regarding the benefits of sperm banking in various countries, like the U.S., Canada is one of the key factors expected to grow sperm bank market

The global sperm bank market is expected to reach a value of USD 4.96 billion by 2025, according to a new report by Grand View Research, Inc. The technological advancements pertaining to assistive reproduction, increasing number of countries legalizing same-sex marriage, and growing government support toward sperm donation and donor offspring in various countries are some of the crucial factors expected to boost the market over the forecast period.

                                  

                                       View summary of this report, Click Here

In 2015, North America held majority of the revenue share of the sperm bank market. The presence of large number of sperm banks and registered laboratories in North America is one of the key factors that can be accounted for the largest share. The regulations for sperm donation vary as per country; most of the countries have limit on the number of donor off springs and prohibition on the sperm usage of a deceased donor.

The increasing prevalence of infertility has led to huge demand for sperms and the presence of favorable government policies pertaining sperm donation and donor offspring are among some of the key factors anticipated to boost the market over the forecast period. Europe is the fastest growing segment owing to the disparity between demand (high) and supply (low) of sperm.

The growing number of insemination procedures, huge demand for known donors, and huge overall cost incurred in analysis and purification for insemination procedures are few of the factors responsible for majority of revenue share of donor insemination segment. However, In Vitro Fertilization (IVF) segment is expected to be the fastest growing segment over the forecast period due to the growing demand for IVF procedures and growing awareness regarding the benefits of IVF over insemination procedures.

Further Key Findings from the Study Suggest:

• In 2015, known donor was the largest donor type segment, owing to the huge cost of known sperms as compared to anonymous
• Despite the presence of huge number of anonymous donors, this segment held a lower share of the overall the market
• In 2015, semen analysis held majority of the revenue share due to the growing R&D, academic research, and assisted reproductive procedures.
• The presence of huge customer base for infertility treatment and withdrawal of one-child policy in China is expected to drive growth in the Asia Pacific region
• Some of the key players are FairFax Cryobank, Inc.; Cryos International; Androcryos; New England Cryogenic Center; Indian Spermtech; European Sperm Bank; Seattle Sperm Bank; Xytex Sperm Bank, and London Sperm Bank.

 For More Information Click Here : https://goo.gl/RDURXJ

Injectable devices which enable the convenient self-injection by the patients are some of the factors expected to fuel the growth of drug and gene delivery system market

The global drug and gene delivery systems market is expected to reach USD 786.9 Billion by 2025, according to a new report by Grand View Research, Inc. Rising investment by the market players to develop innovative drug delivery systems to cater to the demand by the patients as well as to increase the bioavailability at minimum quantity of active pharmaceutical ingredient is driving the market growth. Additionally, increasing focus on R&D of gene delivery systems owing to the high growth potential of gene therapy for the treatment of a wide range of diseases is expected to fuel the market growth in the future.

Drug delivery systems are in a constant evolution along with the changing preference by the patient. For instance, initially, hormone replacement therapy was widely prescribed in the form of pills, whereas, it is now available in the form of prefilled syringes, patches, vaginal rings, gel, and sprays. The principal purpose of development of different forms of delivery systems is to increase the ease of use. Factors such as aesthetics of the delivery systems, price, and amount of API are also considered while designing the drug delivery system.

View summary of this report, Click Here 

Further key findings from the study suggest:

• The market study suggests that oral segment dominated the market in 2015
• The convenience of use and low manufacturing cost are the prime factors responsible for the dominance of the oral delivery segment
• Injectable segment is expected to show a lucrative growth rate owing to the introduction of technically advanced injecting devices that enable convenient self-injection
• North America dominated the market in 2015 and is expected to remain dominant throughout the forecast period owing to highly developed healthcare infrastructure and high healthcare spending
• Asia pacific is expected to exhibit the fastest growth rate during the forecast period owing to the factors such as rapidly developing economies, growing disposable income, and high adaption of the advanced delivery systems
• A few of the major market players in drug delivery systems space are F. Hoffmann-La Roche Ltd, Pfizer, Inc., Johnson and Johnson private Ltd, Novartis AG, Becton, Dickinson and Company, and Bayer AG.
• Major market players in the gene delivery systems space are SiBiono GeneTech Co., Unique N.V., Epeius Biotechnologies Corporation, Human Stem Cells Institute, and Shanghai Sunway Biotech Co., Ltd.

For More Access Click Here: https://goo.gl/j54yEg

Rising patient pool, increasing investment by major players in the region, and rising adoption of gout therapy market

The global gout therapeutics market is expected to reach a value of USD 8.3 billion By 2025, based on a new report by Grand View Research, Inc. The gout therapeutics market is anticipated to witness significant growth during the forecast period. This can be attributed to the introduction of major urate-lowering agents, approval of effective biologics, and increasing number of patients suffering from chronic gout.

In December 2015, AstraZeneca’s product, Zurampic (lesinurad), in combination with xanthine oxidase inhibitor (XOI) received an approval from the U. S. FDA to treat gout. Later in February 2016, the European Commission approved the drug throughout the European Union (EU). Hence, introduction of urate-lowering agents is expected to drive the market.

Introduction of biologics to treat gout and increasing adoption of newer therapies further help propel the industry. For instance, in March 2013, Novartis received an EU approval for the product, Ilaris, for use in the treatment of patients suffering from gouty arthritis.

                                                 View summary of this report, Click Here 

Further key findings from the study suggest:

• Nonsteroidal Anti-inflammatory Agents (NSAIDs) accounted for the highest share of the market in 2015, which can be credited to highest penetration, higher demand due to low cost, and efficient pain relief.
• Urate-lowering agents segment is expected to grow at the highest rate over the coming years. Expected entry of various new drugs, increasing adoption of drugs, and growing investment by key players for development of these agents are likely to drive the segment.
• Chronic gout dominated in 2015 and is expected to maintain its dominance during the forecast period. Approval of new drugs to treat chronic gout and long-term expenditure for treatment are the key factors responsible to propel the industry.
• NSAIDs, colchicine, and corticosteroids are majorly used to treat acute gout, and urate-lowering agents are utilized in chronic gout treatment in combination with NSAIDs or Colchicine.
• Geographically, North America dominated the overall industry in 2015. This is attributed to higher adoption of the newer & expensive treatments and rising awareness about arthritic conditions.
• Asia Pacific is expected to witness highest growth during the forecast period due to growing awareness and increasing healthcare expenditure. Furthermore, growing investment in the region by key players is likely to boost the regional growth.
• Some of the key players are Takeda Pharmaceutical Company Ltd.; Novartis AG; Savient Pharmaceuticals; AstraZeneca plc; GlaxoSmithKline plc; Merck& Co. Inc.; Teijin Pharma Ltd.; and Regeneron Pharmaceuticals.

Click Here For Access Full Report : https://goo.gl/yQ4RBJ

Key Factors May Help To Enhance The Demand Of Devices And Thereby Boost The Growth Of The Cochlear Implants Industry

The global cochlear implants market is expected to reach a value of USD 3.1 billion by 2025, based on a new report by Grand View Research, Inc. The cochlear implants market is anticipated to witness significant growth during the forecast period, which can be attributed to a favorable reimbursement scenario, rising awareness about hearing aids, and increasing adoption of implants.

Furthermore, technological advancements in cochlear implants to make the device more efficient and user-friendly can boost the demand, which is expected to propel the industry during the forecast period. For instance, in September 2016, Cochlear Ltd. launched the world’s thinnest full-length perimodiolar electrode for their cochlear implant. The thin structure of the implant electrode helps to protect the delicate structures of the inner ear.

View summary of this report, Click Here 

Further key findings from the study suggest:

• Unilateral implantation dominated the industry in 2015.This can be attributed to its low cost as compared to bilateral implantation and high demand from adults due to its cost-effectiveness.
• Bilateral implantation is the most lucrative segment of the industry. Increasing demand, ability to recognize the speech in noise, and good reimbursement are the key factors expected to drive the market during the forecast period.
• By end-users, the adults segment dominated the market in 2015 and is expected to maintain its dominance during the forecast period, due to the presence of a large patient base and growing geriatric population.
• Pediatrics segment is expected to grow at the fastest rate during the forecast period. Increasing implantation at an early age, implementation of several programs & government support to provide cochlear implant to children as early as possible, and good reimbursement are the key factors expected to propel the market.
• Geographically, Europe dominated the industry in 2015 and is expected to maintain its position during the forecast period. This is primarily due to the conducive health infrastructure of the European Union, which allows implantation at an early age.
• Asia Pacific is anticipated to observe the fastest growth over the coming years. This can be attributed to growing awareness in the region and local presence of market players.
• Several players operate in the industry. However, majority of the share belonged to the top two to three players who dominated in the industry in 2015.
• Some of the key players are Cochlear Ltd., MED-EL, Sonova, Gaes Group, William Demant Holding A/S, and Nurotron Biotechnology Co. Ltd.

Click Here For Access Full Report : https://goo.gl/31pnyz

Biosimilars: The New Solution to Conventional Drugs

Biosimilar products are split into recombinant non-glycosylated proteins, which include insulin, human growth hormones, among others and recombinant glycosylated proteins that include erythropoietin and follitropin, among others. Growing incidences of cancer, blood disorders, growth hormone deficiency, etc. are predicted to drive the biosimilars market over the forecast period (2016 to 2024).  

Amgen, Inc., recently unveiled their new biosimilar version of AbbVie Inc.’s ABBV rheumatoid arthritis (RA) medicine “Humira”, which has received an approval by the European Commission (EC).  The drug received an approval from U.S. in September 2016, under the name “Amjevita” (adalimumab-atto).

Amjevita is a biosimilar to the drug “Humira” (adalimumab), used to treat other inflammatory diseases namely ankylosing spondylitis (an arthritis that affects the spine), psoriatic arthritis, adult Crohn’s,rheumatoid arthritis (RA), ulcerative colitis (UC), juvenile idiopathic arthritis (JIA), ankylosing spondylitis (AS), plaque psoriasis (PsO)  psoriatic arthritis (PsA), and in patient as a monotheray or combination with methotrexate.

Amjevita is used to help treat moderately to severely active polyarticular juvenile idiopathic arthritis in children four years and above. According to the FDA, Amjevita has been approved as a biosimilar, but not as interchangeable product. FDA approved the drug based on the review of evidences that comprised structural and functional characterization, human pharmacokinetic, pharmacodynamics data, clinical immunogenicity data and other safety and effectiveness data. 

The biosimilars market is expected to reach USD 41.7 billion by 2024; according to a new report by Grand View Research, Inc. Biologics are rapidly approaching patent expiration, can drive the market over the coming years.

Access Full Comprehensive Market Insights: http://www.grandviewresearch.com/industry-analysis/biosimilars-market

Molecular Weight Marker Market Driven By Use in Varied Applications

Molecular weight (MW) markers are standards which determine the size of a molecule during electrophoresis. It is also referred as RNA, DNA, and protein ladder. These markers are run in polyacrylamide or agarose gels. Development of technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) encouraged the use of these markers in molecular biology. Interest in molecular biology research by major corporations is driving the global molecular-weight size marker market. 

PCR-based markers were essential in detecting virus strains in human DNA. The DNA fragments can be cloned multiple times and used for probes and assays. AFLP (amplified fragment length polymorphism), RAPD (Random amplified polymorphic DNA), and microsatellites are different types of these markers. NGS has gained prominence in creating DNA markers on crops. This can be used to tag disease-resistant genes for molecular breeding. 

Microarrays and RT-PCR (reverse transcription polymerase chain reaction) are methods which are used in studying gene expressions in animals. For instance, the one-step RT-PCR kit by Qiagen was used by doctors to detect strains of Crimean-Congo hemorrhagic fever (CCHF) in humans in Bulgaria. It has been used to reduce the rising incidence of deaths due to the disease by providing the right vaccine. Thermo Fisher Scientific offers a variety of DNA ladders available for a range of 10 bp (base pairs) to 12 kb (kilo base pairs) to identify molecular sizes. 

The global molecular-weight size marker market is anticipated to exceed over USD 1 billion by 2025. It stood at USD 355.2 million in 2016. It is expected to expand at a 14.1% CAGR over the forecast period (2014 - 2025). It is driven by the surging demand of personalized medicine to treat chronic diseases.

DNA markers generated huge revenues for the market in 2016 and expects to grow at a significant rate during the forecast period. Proteomics application can grow robustly over the same period driven by clinical diagnostics and drug discovery. Asia Pacific market can expand at a significant growth rate over the forecast period due to rising focus of contract research organizations in DNA ladders. Prominent players comprise Promega Corporation; New England Biolabs; Thermo Fisher Scientific, Inc.; and Qiagen. 

Read More: http://www.grandviewresearch.com/industry-analysis/molecular-weight-marker-market

Dermatology Devices Market Driven by Technological Innovations

Dermatology devices are devices and related adjuncts which aids dermatologists to treat skin disorders. Some of these devices are imaging devices, radiofrequency (RF) devices, cellulite-reducing devices, microdermabrasion devices, and lasers. It can aid in detecting skin cancer in its early stages. The demand of non-invasive techniques to treat such diseases is driving the global dermatology devices market. Alarming rise of obese populace is also expected to contribute to market growth. 

RF devices are considered to be the safest method for skin rejuvenation. Developments in these devices have led to better facial laxity and improvement regarding rhytides. At-home devices are a boon for consumers who wish to treat their skin within the confines of their houses. Blue LEDs (light-emitting diode) have the capacity to neutralize bacteria which contribute to inflammatory acne. Cellulite-reducing devices like SculpSure (Cynosure) possess the capacity to reduce body fat levels sufficiently. 

Developments in these devices have also led to its application in other areas such as burns and cancer diagnosis. RenovaCare’s SkinGun has the ability to treat burns by using stem cells of the patient. This treatment has a future potential to replace skin grafts. Damae Medical, a French startup, has developed an advanced imaging system (“Damae Medical System”) to detect tumors in its early stage. Its in vivo analysis can estimate the chances of tumor removal as well as follow up on its recurrence. 

The worldwide dermatology devices market is expected at USD 26 billion by 2025. It is anticipated to grow at a significant CAGR over the forecast period (2014 - 2025). It is driven by awareness of esthetic-related procedures among consumers regarding dermatology devices. Prevalence of various hair and skin related disorders are expected to drive market growth over the forecast period.

Diagnostic and treatment devices are two major products of the market. The former dominated the market in 2015 on account of being accepted by consumers to treat skin disorders. Hospitals were the biggest market end-user in 2015. Asia Pacific is expected to exhibit a lucrative CAGR over the forecast period. Key players in the global market are Cynosure, Inc.; Valeant Pharmaceuticals International Inc.; Avita Medical Ltd.; and GE Healthcare. 

Access Full Market Insights: http://www.grandviewresearch.com/industry-analysis/dermatology-devices-market

Global Coronary Artery Bypass Graft (CABG) Market to Expand With Innovative Methods

Coronary artery bypass graft (CABG) is a surgical procedure used in treating patients with cardiovascular disorders. It is one of the methods used to unclog obstructions to the heart. These obstructions are plaque within coronary arteries due to cholesterol and unwanted lipids. It is also known as coronary artery bypass surgery. CABG remains popular due to development of minimal invasive techniques like the minimally-invasive direct CABG (MIDCAB). The globally increasing geriatric populace which is susceptible to cardiovascular disorders (CVDs) is anticipated to drive the bypass surgery graft market. 

CABG is performed on 75% cases of patients with sudden cardiac arrest. Developments in CABG have led to endoscopic computer (robotics)-assisted CABG (C-CAB), full-sternotomy “off-pump” CABG (OPCAB), and port-access CABG (P-CAB). OPCAB techniques enjoyed a 60% approval rate in Japan, China, and India. Coronary artery bypass surgery enjoyed a longer survival rate in 80% of patients with stage 3 chronic kidney disease (CKD), according to a study by Toronto General Hospital. 

Innovations in the market have led to the development of advanced devices like heart positioners which facilitate during surgery. For instance, MAQUET Holdings launched the HEARTSTRING III proximal system to aid surgeons during OPCAB. This device reduces the reliance on occlusion clamps to perform saphenous or radial artery grafts. Partnerships have become common to gain market shares as evident with the collaboration between Estech Corporation and Terumo Cardiovascular Systems. Terumo has agreed to distribute the products offered by Estech for off-pump and on-pump procedures. 

The worldwide coronary bypass graft (CABG) market is projected to reach nearly USD 128 million by 2025. It is projected to expand at a 5.8% CAGR over the forecast period (2014 - 2025). It is driven by increasing cases of CVDs and technologically advanced devices to assist in CABG. On the basis of CABG types, saphenous vein graft surgery is expected to grow at a significant rate over the forecast period. 

Endoscopic vein harvesting technique is expected to gain market shares due to reduced complications as compared to conventional vein harvesting. North America can dominate the CABG market throughout the forecast period due to the growing populace and increased healthcare per capita expenditure. Key market players comprise Vitalitec, MAQUET Holding B.V. & Co.KG, Terumo Corporation, and Medtronic. 

Read More: http://www.grandviewresearch.com/industry-analysis/coronary-artery-bypass-graft-cabg-market

Biologics Market Driven by Demand to Treat Autoimmune Disorders

Biologics are medicines derived from living cells to treat and prevent chronic diseases like rheumatoid arthritis. Their structure is smaller than regular drugs but is far more effective at tackling such diseases. These medicines include monoclonal antibodies (mAbs), recombinant proteins, vaccines, and fusion proteins. Recombinant DNA technology is utilized to remove or add specific genes to a drug to increase its potency. The aging populace which is susceptible to autoimmune disorders is expected to drive the global biologics market. 

Biosimilars and biobetters are preferred alternatives to biologics due to their low production cost. Although they share similar traits to biologics, they are considered to be safer and effective drugs. Major companies like Amgen are investing in this market to increase their reach. Additional factors influencing this move are patent expiry of major drugs such as Humira and Herceptin as well as acceptance of biosimilars by various federal agencies like the US Food & Drug Administration. But the setup of better delivery models to meet growing consumer demands can influence market growth. 

Companies are turning to contract manufacturing organizations (CMOs) to expedite their production process. CMOs are adapting new expression systems and single-use technologies to reduce production costs. This would also lower the prices of biopharmaceuticals, making it affordable for the consumer. This move would allow the companies to expand their R&D expertise. Other trends include the outsourcing of production to China and India due to their mature technical expertise.

The worldwide biologics market is anticipated at nearly USD 400 billion by 2025. It is expected to expand at a CAGR nearing 4% over the forecast period (2014 - 2025). It is driven by surging demand of targeted therapies and personalized medicines to treat autoimmune disorders and various cancers.

Microbial systems were the preferred source of biologics in recent years. It is being used to produce granulocyte colony-stimulating factor (G-CSF) and recombinant proteins. Monoclonal antibodies (mAbs) had dominated the global market, on revenue basis, due to being used in production of various medicines. Prominent market players are Pfizer Inc.; Eli Lilly & Company; Merck & Co. Inc.; and AbbVie Inc.

Access Full Market Insights: http://www.grandviewresearch.com/industry-analysis/biologics-market

Atherectomy Devices Market Driven by Technologically Advanced Devices

Atherectomy is a medical procedure performed by cardiology interventionists in treating peripheral artery disease (PAD). It can restore normal blood flow by removing plaque from the arteries. It can also treat other forms of PAD like critical limb ischemia (CLI) and claudicant. It is highly prevalent in patients above the age of 40 according to a report by the National Health and Nutrition Examination Survey. The high prevalence of PAD globally is expected to drive the worldwide atherectomy devices market.

The different types of devices used for this procedure are rotational, laser, directional, and orbital devices. Laser atherectomy has a 93% success rate in treating target lesion revascularization (TLR) in patients. Recently, Cardiovascular Systems Inc. received U.S. FDA (Food & Drug Administration) clearance for its Diamondback 360 Peripheral Orbital Atherectomy System. Its smaller size prevents medical complications.

Technological advances in atherectomy devices can remove even calcified plaque. Shockwave Medical has developed an angioplasty balloon which contains lithotripsy emitters. It is in the early stage of development but has seen success in trials in Europe. Medtronic’s two devices (“SilverHawk” and “TurboHawk”) have gained U.S. FDA approval in 2016. Both these devices can be used without the use of stents or percutaneous balloon angioplasty. It can reduce the chances of barotraumas and neointimal hyperplasia.

The worldwide atherectomy devices market is anticipated to reach USD 895 million by 2025. It was estimated at USD 488.04 million in 2016. It is expected to grow at a 7% CAGR over the forecast period (2014 - 2025). The market is driven by the increasing demand of minimally invasive surgery. Rising incidence of peripheral artery disease (PAD) is expected to spur market growth.

Directional atherectomy devices led the global market, on the basis of revenue, in 2016. This can be attributed to its capability to reduce the chances of barotrauma and neointimal hyperplasia. North America was the market leader in 2016 due to the FDA approval of medical devices and suitable reimbursement packages in the region. Key players in the global market are Spectranetics, Boston Scientific Corporation, Terumo IS (Interventional Systems), and Medtronic (Covidien).

Access Full Market Insights: http://www.grandviewresearch.com/industry-analysis/atherectomy-device-market

Antibody Production Market Driven by Immense Demand of Therapeutics

Antibodies are Y-shaped proteins produced in the immune system to thwart the attack of bacteria and viruses. They target these harmful agents by identifying the antigens. It is also known as immunoglobulin (Ig). These antibodies are manufactured by biopharmaceutical and biotechnology companies using the cell gene expression system. Monoclonal (mAbs) and polyclonal (pAbs) antibodies are artificial immune cells created by these companies to target specific cells for better treatment of cancer and blood disorders. The increasing demand of these antibodies is driving the antibody production market. 

Technological advances in the market have led to the development of antibody-drug conjugates (ADCs). These antibodies are able to target cancer cells without affecting any healthy cells. This drug delivers a cytotoxic agent using cell surface markers. The U.S. Food & Drug Administration (FDA) approved Seattle Genetics’ Adcetris and Kadcyla in 2011. Further developments of these drugs have made them non-cleavable and alleviate the chances of it affecting healthy cells. 

Participants in the market still employ the use of cell gene expression system to produce these Ig’s. The purity of these antibodies affects the potency of the drug or medicine. Sutro Biopharma, Inc., a US-based pharmaceuticals manufacturer, uses cell-free protein synthesis technology to overcome these limitations. This technology allows the development of different variations of antibodies, allowing the best ADCs to be selected. Other companies are employing the services of contract manufacturing organizations (CMOs) to expedite their production process. 

The world antibody production market is anticipated at USD 23 billion by 2025. It was estimated at USD 7.4 billion in 2016. The market is primarily driven by the increasing demand of therapeutic antibodies. Patent expiry of various mAbs drugs has prompted many biopharmaceuticals to develop advanced antibodies.

mAbs segment has generated maximum revenue for the market in 2016. This segment is driven by demand of these drugs in treating cancer and blood disorders. Upstream processing and filtration segments are expected to generate lucrative returns over the forecast period (2014 - 2025). North America will continue to dominate the market over the forecast period due the presence of various biopharmaceutical companies in the region. Prominent market players are Pall Corp., INTEGRA Biosciences AG, Cellab GmbH, and Merck KGaA.

Read More: http://www.grandviewresearch.com/industry-analysis/antibody-production-market

Control Measures Taking Place In The Process Of Drug Discovery Is Majorly Triggering Growth of Mycoplasma Testing Market

The global mycoplasma testing market is expected to reach a value of USD 1.4 billion by 2025, according to a new report by Grand View Research, Inc. With growing R&D investments in the field of life sciences, the demand for mycoplasma testing products are anticipated to rise in the near future. Huge opportunities in the life sciences segment are spurring the market growth. Hence, a large amount of investment is being made in the biotechnology and pharmaceutical industries with rising level of healthcare spending across the globe. This is expected to trigger high growth of mycoplasma testing market.

Investment in R&D activities by pharmaceutical and biotechnology companies is increasingly being supported by the government. Researches involving drug discovery and development, receive funding from the governmental bodies to a great extent. Moreover, governmental initiatives in the form of awareness campaigns for chronic diseases such as cancer are also encouraging research-based activities. Thus, the aforementioned factors are expected to drive the market growth.

Mycoplasma contamination of cell culture is a growing concern for most of the research scientists for decades. Mycoplasma infection arises majorly from laboratory workers as human mycoplasma contamination occurs at a faster rate. In order to combat further contamination, mycoplasma tests are being conducted, which is expected to increase the demand of the related products.

View summary of this report, Click Here 

Further Key Findings From the Study Suggest:

• In 2016, kits & reagents dominated the market and is also expected to show highest CAGR over the forecast period owing to its wider application in mycoplasma tests
• Amongst the technology segment, Polymerase Chain Reaction (PCR) held the largest share in 2016 owing to the delivery of fast & accurate results associated with this technology
• Cell line testing is anticipated to exhibit highest CAGR over the forecast period due to the increasing risk of cell line contamination
• In 2016, pharmaceutical and biotechnology companies accounted for the largest market share due to rising number of research activities in drug discovery and development
• North America dominated the market in 2016 owing to rising healthcare spending levels and government funding for life science-related research
• Some of the key players are Merck KGaA; Sigma-Aldrich Co.; Thermo Fisher Scientific; Lonza Group Ltd.; Charles River Laboratories International, Inc.; PromoCell GmbH; and Bionique Testing Laboratories, Inc.

Click Here For Access Full Report: https://goo.gl/9Uv7PK

Promote Awareness Pertaining To Efficient Prevention Measures Globally, Which Is Expected To Contribute Of Infection Control Market Growth

The global infection control market is expected to reach USD 258.3 billion by 2025, according to a new report by Grand View Research, Inc. The market is driven by rising concerns with respect to a significant upsurge in hospital acquired infections globally. This is believed to facilitate greater penetration of infection control products. An influx in development of new biologics and subsequent demand for sterilized formulations serve as key growth factors for the overall infection control market. The healthcare organizations are focused on implementing strategies for early recognition, reporting, isolation, and surveillance of disease episodes of potential public health concern. In addition, increasing number intensive training modules, for nurses and other medical staff, on infection prevention and control is presumed to provide high potential for extensive usage of infection control products over the coming years.

For instance, College of Nurses of Ontario released guidelines concerning standard practices, that is focused on maintaining hand hygiene to reduce contamination and spread of infection. Furthermore, Centers for Disease Control and Prevention (CDC) has released guidelines for disinfection and sterilization for efficient usage of infection control products by healthcare personnel in wide array of healthcare settings such as ambulatory care, home care, hospitals, and others. As a consequence of the aforementioned factors, it is presumed that there will be significant improvement in the overall penetration rate of infection prevention and control products, which is also anticipated to fuel the market demand as well as the revenue to unprecedented heights.

View summary of this report, Click Here 

Further key findings from the report suggest:

• In the type segment, services are predicted to observe exponential growth as a consequence of increasing presence of third-party reprocessors and outsourcing of sterilization as a result of associated cost efficiency
• In the end-use segment, hospitals accounted for substantial share in 2016, as a consequence of high clinical urgency to curb the growing incidence of hospital acquired infections
• North America captured a dominant share of the overall infection control market owing to extensive infection prevention activities being implemented in hospitals, medical device and pharmaceutical companies
• The market in Asia Pacific is projected to witness exponential growth during the forecast period as a result of increasing awareness pertaining to spread of infections within healthcare settings and measures for prevention
• The competitive environment is marked by companies adopting sustainability strategies such as geographical expansion and mergers & acquisitions resulting in significant growth in their market share
• For instance, in July 2016, the Getinge Group acquired 1stCall Mobility Ltd, a company specializing in supplying rental equipment. This acquisition was carried out as a part of the company’s expansion strategy

Click Here For Access Full Report : https://goo.gl/Bf9psm

Weight Management Made Easier with Smart Wearables!

Fast and easy foods to match our fast and hectic requirements have given rise to weight gain and obesity. Excess weight has got with it health problems such as diabetes, hypertension, orthopedic, and other health problems. This has given rise to an awareness regarding weight loss and management.  

The New Gizmo in Town

LVL Kickstart is the first wearable to monitor body hydration in real time. This little smart wearable keeps a tab on the heart rate, hydration level, and activity to optimize the workout regime. It provides the wearer with real-time alerts of how much fluid they require and the best performance boost they require.

LVL use infrared light to measure the water content in the blood altering the wearer of how much and when to drink water. It also tracks activities using distance, step, and calorie tracker. The wearable provides continuous heart rate (HR) monitoring and training. 

Exercises and food & nutrition are integral parts of weight management. For effective weight loss, the body also requires adequate rest and sleep to allow the body to recuperate. LVL comes with added feature to track advanced REM (Rapid Eye Movement), automatic sleep tracking with a smart alarm, and deep sleep metrics. LVL goes a step further and provides mood inputs allow the gadget to predict how well the user will sleep, perform their activities, and how it will in turn affect their future moods. 

The gadget is BLE (Bluetooth) enabled and can communicate with phones, tablets, watches, and other devices. The LVL comes with a free mobile app that is compatible with both iOS as well as Android devices. The fitness wearable also allows the wearer to see historical trends and patterns using their mobile app. The device comes with an internal memory to store integral information when the phone is not nearby.  

Market Insights

The weight management market is expected to reach USD 442.3 billion by 2025; according to a new report by Grand View Research, Inc. Urbanization, unhealthy eating and lifestyle habits coupled with hectic and sedentary lifestyle has given rise to weight gain and obesity.

Competitive Insights

Ethicon Endo-surgery, Inc.; Ethicon US, LLC: Herbalife International, Inc.; and GOLD’S GYM are some of the key participants of the weight management market. Globally, these companies hold strong positions, which are mainly due to the lack of availability of their products and services commercially. 

Read More: http://www.grandviewresearch.com/industry-analysis/weight-management-market

North America OTC hyaluronic acid (HA) market is expected to reach a value of USD 41.3 billion by 2024

The increasing number of obese people owing to the lack of physical activity and higher consumption of fast food & alcohol, especially by the younger population are some of the factors accounting for growth.

View summary of this report, Click Here 

Orthopedic applications of HA are expected to emerge as the most lucrative segment of this market. This can be attributed to the growing target audience above 60 years, suffering from various joint disorders such as rheumatoid arthritis and osteoarthritis coupled with the introduction of new products catering to this population subset. In addition, increase in the number of arthritis-related hospitalization cases and growing awareness amongst the healthcare professionals regarding excellent physiochemical properties of hyaluronic acid is expected to drive the demand. However, the dermatology segment in the U.S. was the largest segment in 2015 accounting for almost 95.2% of the total U.S. OTC hyaluronic acid market. The growing population of women between 20 and 65 years of age and increasing awareness regarding the benefits of HA are some of the crucial factors driving the surging demand for hyaluronic acid in dermatological procedures.

Hyaluronic acid (HA) stimulates the synthesis of a protein that plays a crucial role in supporting skin structure and collagen, which declines with age leading to wrinkle formation. The growing demand for HA as a topical skin cream or serum coupled with the increasing presence of market participants in this sector is indicative of future growth. The rising awareness regarding the benefits of HA in skin care products for penetrating the dermis more effectively as compared to collagen is also anticipated to propel the market trend. According to various reports, approximately 27% of the total U.S. women population belong to the age group of 45 to 65 years, which is one of the crucial factors responsible for the surging demand for anti-wrinkle creams.

Some of the key players are Shiseido Co., Ltd.; Lindberg Nutrition & GeniusCentral Systems; Nature’s Way Products, LLC; NOW Foods; NeoCell Corporation; Source Naturals, Inc.; Doctors Best; derma e; and Earth Science Naturals

Click Here For Access Full Report : https://goo.gl/zog9y3

Revenue Cycle Management (rcm) Market Is Expected To Reach USD 65.2 Billion By 2025

The healthcare system is witnessing a paradigm shift primarily due to the changing dynamics of the business models.

These changing dynamics of the hospital industry in developed regions is expected to involve centralization and digitalization of the back-end processes, thereby demanding the implementation of revenue cycle management, which is anticipated to positively affect the market growth.

The healthcare industry is extremely vast and its centralization will help in synchronizing the entire work process along with providing economic benefits. Almost all industries aim to achieve lean management and six-sigma incorporation in their work culture to optimize resource usage and increase efficiency.

Furthermore, development of value-added services, i.e., integration of RCM system with other healthcare IT solutions such as practice management, Electronic Health Record (EHR), Computerized Physician Order Entry (CPOE) is anticipated to propel demand over the forecast period. For instance, Kareo, Inc. are multiple software enlisted in their portfolio that find high application in integrated solutions along with being used as standalone options.

View summary of this report, Click Here 

Further Key Findings From The Study Suggest:

• Services are expected to witness highest growth at a CAGR of over 11.0%. In particular, denial management and accounts receivable services are expected to be highly outsourced over the forecast period.
• Integrated solutions are anticipated to be the fastest growing segment. These can be used cohesively along with various other software to enhance efficiency and communication across different departments.
• The web-based segment is predicted to dominate the RCM market in 2025. These services are more affordable than cloud-based solutions.
• Hospitals and other end-users are expected to be the most lucrative segments over the next 8 years. To further support the segment, physician offices are also expected to contribute stable revenue, thereby promoting overall market growth.
• Asia Pacific followed by Latin America are expected to report fastest CAGR for the next 9 years. Furthermore, regions in MEA such as Saudi Arabia, Egypt, and Abu Dhabi, which are currently undergoing IT infrastructure development are expected to present lucrative opportunities.
• Major participants include McKesson Corporation; Epic Systems; Cerner Corporation; CareCloud Corporation; Kareo, Inc.; The SSI Group, LLC; Quest Diagnostics, Inc.; eClinicalWorks; athenahealth, Inc.; and Allscripts. Other firms include AdvantEdge Healthcare Solutions, Anthelio Healthcare Solutions, Greenway Health, LLC; and NextGen Healthcare

Click Here For Access Full Report : https://goo.gl/mLW2ry

Immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025

The global immunohistochemistry (IHC) market is estimated to reach a value of USD 3.1 billion by 2025, according to a new report by Grand View Research, Inc. The rising prevalence of cancer and increasing healthcare expenses driven by expanding aging population base are recognized to be the most influential factors driving the growth of the immunohistochemistry market. Furthermore, the rapid growth of biotech industry highlighted by increase in growth and revenue coupled with increase in stock market capitalization will nurture the growth.

Cancer has high morbidity and mortality risk associated with them. The diagnosis of the disease is majorly dependent on the stage of the disease at admission. This has led to the high demand of immunohistochemistry products. IHC staining process is performed on cancer tissues to reveal the presence of HER2 receptors and/or hormone receptors on their surface. This information plays a vital role in planning the treatment for the disease, creating a demand for immunohistochemistry products. In addition, the rising popularity of targeted immunotherapy and biologic therapy for anticancer drug development and the increasing approvals of the same by the FDA to treat specific types of cancer are expected to benefit the growth in the long run.

Other important factors driving growth include the alarming rise in healthcare spending and the shift in focus on value-based healthcare solutions. In 2015, the U.S. healthcare spending witnessed an increase of 5.8% to reach a value of USD 3.2 trillion. To curb the issue and establish a more value-based healthcare delivery, hospitals and care facilities are adopting a more specific and targeted therapy for better outcomes.

View summary of this report, Click Here 

Further key findings from the study suggest:

• North America registered the largest growth rate in the immunohistochemistry market in 2016
• The APAC region is expected to witness the fastest growth owing to increasing healthcare expenses driven by expanding aging population offering significant growth opportunities for players
• The hospitals and diagnostic laboratories segment accounted for the largest share of the immunohistochemistry market, by end-use due to the growing application of immunohistochemistry products for diagnostic procedures
• The antibody segment accounted for the largest share of immunohistochemistry market due to the increase in approvals by regulatory bodies for therapeutic antibody products
• Key players mapped in the report include Abcam plc, Agilent Technologies, BioSB, Cell Signaling Technology, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd, Merck Millipore, PerkinElmer Inc., and Thermo Fisher Scientific Inc.

Click Here For Access Full Report : https://goo.gl/ewktF3

Electronic Data Capture (EDC) Systems Market Growth Is Expected To Reach USD 1.16 Billion By 2025

The rising demand for software solutions in clinical trials, increasing R&D expenditure by companies in healthcare, supportive government initiatives to boost trials, and increasing number of potential customers implementing Electronic Data Capture (EDC) systems are some of the key factors contributing to the market growth.

The market is growing rapidly owing to the technological advancements in eClinical solutions and this is anticipated to serve this industry with future growth opportunities. Furthermore, increasing awareness pertaining to EDC solutions is predicted to fuel the demand in near future. Moreover, government organizations such as Agency for Healthcare Research and Quality and The Office of National Coordinator for Health Information Technology are promoting the adoption of electronic systems for data management. The aforementioned factors have resulted in the rising adoption of electronic data collection by pharmaceutical companies.

Moreover, increasing adoption of EDC systems by major pharmaceuticals to propagate clinical trials is predicted to provide this market with lucrative growth. For instance, in May 2016, Simbec-Orion Group selected Oracle's product, the Siebel Clinical Trial Management System, to strengthen its development processes and to expand its international operations & business. The system will provide efficient data capture and speed up the trial timelines. The strategies like this are anticipated to boost demand in coming years.

                           View summary of this report, Click Here 

Further Key Findings From the Study Suggest: 

• The software segment is predicted to witness lucrative growth owing to growing adoption by large pharmaceutical companies
• The cloud-based segment is anticipated to experience the fastest growth as it allows easy data access over remote locations and provides larger storage space
• Phase I clinical trials segment is expected to exhibit fastest CAGR over the forecast period as consequence of the rising R&D expenditure on the development of novel drugs by pharmaceutical companies
• CROs held the largest revenue share of EDC systems owing to rising demand from major players in the medical device sector
• Asia Pacific market for EDC systems is anticipated to witness highest growth rate owing to the presence of large number of outsourcing firms in this region offering cost-efficient eClinical solutions
• The market is facing intense competition as there are many organizations that offer technologically efficient solutions for clinical data management
• Companies are adopting strategies such as merger & acquisition, new product development, and distribution channel enhancement to gain competitive advantage

Click Here For Access Full Report : https://goo.gl/AvFbFW